Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients (Q46748800)

24 December 2017

title

Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients (English)

1 reference

24 December 2017

positron emission tomography

main subject

glucose

0 references

1 reference

Barbara J Fueger

1

1 reference

24 December 2017

Wolfgang A Weber

2

1 reference

24 December 2017

Andrew Quon

3

1 reference

24 December 2017

Tyler L Crawford

4

1 reference

24 December 2017

M S Allen-Auerbach

5

1 reference

24 December 2017

B S Halpern

6

1 reference

24 December 2017

Osman Ratib

7

1 reference

24 December 2017

Michael E Phelps

8

1 reference

24 December 2017

Johannes Czernin

9

1 reference

24 December 2017

publication date

1 September 2005

1 reference

24 December 2017

Molecular Imaging and Biology

published in

1 reference

24 December 2017

volume

7

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

369-376

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1007/s11307-005-0013-4

exact match

0 references

cites work

Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11307-005-0013-4

Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-005-0013-4

Osteocyte density in woven bone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-005-0013-4

Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-005-0013-4

Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11307-005-0013-4

FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls

21 January 2018

1 reference

12 December 2020

18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer

1 reference

12 December 2020

The role of positron emission tomographic imaging in breast cancer

1 reference

12 December 2020

Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography

1 reference

12 December 2020

Radiologic diagnosis of bone metastases

1 reference

12 December 2020

Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.

1 reference

12 December 2020

Spinal computed tomography scanning in the evaluation of metastatic disease

1 reference

12 December 2020

Advantages and limitations of FDG PET in the follow-up of breast cancer

1 reference

12 December 2020

Clinical and radiographic correlations in breast cancer patients with osseous metastases

1 reference

12 December 2020

Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography.

1 reference

12 December 2020

The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases

1 reference

12 December 2020

Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET

1 reference

12 December 2020

Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations

1 reference

12 December 2020

Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region

1 reference

12 December 2020

18-FDG imaging in breast cancer

1 reference

12 December 2020

F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging

1 reference

12 December 2020

Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group

1 reference

12 December 2020

Attenuation correction for a combined 3D PET/CT scanner

1 reference

12 December 2020

Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.

1 reference

12 December 2020

Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability

1 reference

12 December 2020

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.

1 reference

12 December 2020

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions

1 reference

12 December 2020

"USA-Fat": prevalence is related to ambient outdoor temperature-evaluation with 18F-FDG PET/CT.

1 reference

12 December 2020

Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability

1 reference

12 December 2020

Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations

1 reference

12 December 2020

A combined PET/CT scanner for clinical oncology.

1 reference

12 December 2020

Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients.

1 reference

12 December 2020

10.1007/S11307-005-0013-4

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017